Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
Expert Rev Gastroenterol Hepatol. 2023 Dec;17(12):1169-1183. doi: 10.1080/17474124.2023.2295496. Epub 2024 Jan 17.
Risankizumab is a humanized monoclonal antibody that selectively inhibits interleukin (IL)-23. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, and more recently moderate-to-severe Crohn's disease (CD).
After examining the current landscape of CD management including therapies which are currently approved and those in late stages of development, we will review the interleukin pathway and discuss the specific mechanism of targeted IL-23 inhibition, summarize available clinical trial data on efficacy and safety of Risankizumab, consider future positioning of Risankizumab in the therapeutic armamentarium, and ultimately discuss future needs for the field.
Risankizumab represents the first and only targeted IL-23 inhibitor approved for the treatment of CD, providing a promising addition to the therapeutic armamentarium for CD, with a favorable safety profile and demonstrated efficacy in both biologic-naïve and exposed populations. It is possible that the targeted nature of Risankizumab may enhance efficacy and safety over combined IL-12/23 inhibition, with trials underway attempting to shed light on that hypothesis.
利纳西珠单抗是一种人源化单克隆抗体，能选择性抑制白细胞介素（IL）-23。该药已获批用于治疗中重度斑块型银屑病、银屑病关节炎，以及最近的中重度克罗恩病（CD）。
在考察了 CD 管理的现有格局，包括已获批和处于后期开发阶段的疗法之后，我们将回顾白介素通路，并讨论靶向 IL-23 抑制的具体机制，总结利纳西珠单抗在疗效和安全性方面的现有临床试验数据，探讨该药在治疗领域的未来定位，最终讨论该领域的未来需求。
利纳西珠单抗是首个也是唯一获批用于治疗 CD 的靶向 IL-23 抑制剂，为 CD 的治疗手段提供了一个有前景的补充，具有良好的安全性和在生物初治和暴露人群中的疗效。利纳西珠单抗的靶向特性可能会提高疗效和安全性，超过联合抑制 IL-12/23，目前正在进行试验以验证这一假设。
